All Posts
M-A | Efficacy and safety of ketamine vs. electroconvulsive therapy among patients with major depressive episode.
20 Oct, 2022 | 12:30h | UTCEfficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis – JAMA Psychiatry (free for a limited period)
Commentary on Twitter
While #ElectroconvulsiveTherapy may be more efficacious than #ketamine for #depression severity in the acute phase, treatment options should be individualized and patient-centered. https://t.co/4poayVgsTG
— JAMA Psychiatry (@JAMAPsych) October 19, 2022
Review | Update on the management of upper gastrointestinal bleeding.
20 Oct, 2022 | 12:29h | UTCUpdate on the management of upper gastrointestinal bleeding – BMJ Medicine
Cohort Study | Use of straighteners and other hair products and incident uterine cancer.
20 Oct, 2022 | 12:28h | UTCNews Release: Hair straightening chemicals associated with higher uterine cancer risk – NIH News Releases
Commentaries:
Hair-straightening chemical products linked to increased uterine cancer risk in new study – CNN
Hair straightening chemicals may increase women’s risk of uterine cancer, study finds – NPR
Cohort Study | Intravenous potassium and magnesium linked to spontaneous conversion of atrial fibrillation in the ED.
20 Oct, 2022 | 12:27h | UTC
Commentary on Twitter
IV potassium and magnesium was associated with higher rates of conversion in atrial fibrillation but not flutter during patients’ emergency department stays. https://t.co/p3nQK8zNMs
— JAMA Network Open (@JAMANetworkOpen) October 19, 2022
RCT | Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn’s disease.
20 Oct, 2022 | 12:26h | UTCEtrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn’s disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial – The Lancet Gastroenterology & Hepatology (free registration required)
Commentary: Etrolizumab Increases Chance of Clinical Remission for Crohn’s Disease – HCP Live
Commentary on Twitter
New research – Sandborn et al – Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn’s disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial https://t.co/I81bEfz5WU#IBD #GITwitter #UEGWeek pic.twitter.com/lwnl1EI7cz
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) October 12, 2022
Cohort Study | Associations of hypertriglyceridemia onset age with cardiovascular disease and all‐cause mortality in adults.
20 Oct, 2022 | 12:25h | UTC
M-A of RCT | Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis.
20 Oct, 2022 | 12:25h | UTCCarvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis – Journal of Hepatology (link to abstract – $ for full-text)
Commentary on Twitter
#Carvedilol
➡️non-selective #βblocker
✅associated with reduced risk of decompensating events
➡️improved survival in patients with #cirrhosis & #portalhypertensionRead it here👉https://t.co/yy8DIJBhfL#LiverTwitter pic.twitter.com/XxmrB7gff8
— Journal of Hepatology (@JHepatology) October 13, 2022
Cohort Study | Genetic sequencing of pancreatic cyst fluid reveals diverse genomic alterations that may guide clinical management.
20 Oct, 2022 | 12:24h | UTCNews Release: Genetic test for pancreatic cancer outperforms current guidelines – University of Pittsburgh
Commentary from the author on Twitter (thread – click for more)
A tweetorial on our study (https://t.co/OCqCRJEMdx). But, first a case: Young female w/ a 1.9 cm incidental pancreatic cyst. No concerning features, but KRAS, TP53 and SMAD4 mutations on molecular testing. Surgical resection: #IPMN w/ a small #PancreaticCancer. #Pathology #GIPath pic.twitter.com/hMJQ4OAUld
— Aatur Singhi, MD PhD (@PancPathologist) October 10, 2022
Cross-sectional study | Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease.
20 Oct, 2022 | 12:22h | UTC
Commentary on Twitter
The Lp(a) Heritage study, in prep for Lp(a) HORIZON, is now out- 48,129 pts eligible otherwise for Lp(a) HORIZON, with survey of Lp(a) levels. Data shows a higher prevalence of ⏫levels in pts with ASCVD vs general population at >70 mg/dL/>150 nmol/L https://t.co/lcp0gSLhCJ pic.twitter.com/DBGBNk0SOa
— Sam Tsimikas, MD (@Lpa_Doc) October 18, 2022
Under a http://creativecommons.org/licenses/by-nc/4.0/ license
Pro-Con Debate | The clinical (Ir)relevance of the lower limit of cerebral autoregulation for anesthesiologists.
20 Oct, 2022 | 12:23h | UTCPro-Con Debate: The Clinical (Ir)relevance of the Lower Limit of Cerebral Autoregulation for Anesthesiologists – Anesthesia & Analgesia (free for a limited period)
Review | Cardiac care of children with Duchenne muscular dystrophy (DMD) and females carrying DMD-gene variations.
20 Oct, 2022 | 12:21h | UTCCardiac care of children with dystrophinopathy and females carrying DMD-gene variations – openheart
Development of a pediatric blood pressure percentile tool for clinical decision support.
20 Oct, 2022 | 12:20h | UTC
Cohort Study | BMI in adolescence and long‐term risk of AF and subsequent mortality, heart failure, and ischemic stroke.
20 Oct, 2022 | 12:20h | UTC
RCT | Lurbinectedin plus Doxorubicin are no better than physician’s choice of chemotherapy in relapsed small-cell lung cancer.
20 Oct, 2022 | 12:19h | UTCCombination lurbinectedin and doxorubicin versus physician’s choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
Commentary on Twitter
NEW—Lurbinectedin + doxorubicin did not improve overall survival vs control in relapsed SCLC., but did show a favourable haematological safety profile
ATLANTIS trial from Prof Luis Paz-Ares & colleagues https://t.co/oF57GJx7u1 pic.twitter.com/8aoqTqXUl7
— The Lancet Respiratory Medicine (@LancetRespirMed) October 17, 2022
Crossover RCT | Spinal cord burst stimulation does not improve disability in chronic radicular pain after lumbar spine surgery.
19 Oct, 2022 | 14:29h | UTCEffect of Spinal Cord Burst Stimulation vs Placebo Stimulation on Disability in Patients With Chronic Radicular Pain After Lumbar Spine Surgery: A Randomized Clinical Trial – JAMA (free for a limited period)
Commentary on Twitter
Among patients with chronic radicular pain after lumbar spine surgery, spinal cord burst stimulation, compared with placebo stimulation, resulted in no significant difference in back pain–related disability. https://t.co/XGiRRB4Njm #Research
— JAMA (@JAMA_current) October 18, 2022
Cohort Study | Association of hyperopia with incident clinically significant depression.
20 Oct, 2022 | 12:18h | UTCCommentary: Older Individuals with Hyperopia More Likely to Develop Incident Depression – HCP Live
Pooled analysis of cohort studies | Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters.
19 Oct, 2022 | 14:28h | UTCCommentaries:
Prioritisation of COVID-19 boosters in the omicron era – The Lancet
COVID booster halved severe illness, but some groups still at higher risk – CIDRAP
RCT | Efficacy of BCG vaccination in reducing the incidence and severity of COVID-19 in a high-risk population.
19 Oct, 2022 | 14:26h | UTC
Case-control study | Odds of hospitalization for COVID-19 after 3 vs. 2 doses of mRNA vaccine by time since booster dose.
19 Oct, 2022 | 14:27h | UTC
Consensus Paper | Surgical management of giant pituitary neuroendocrine tumors.
19 Oct, 2022 | 14:25h | UTC
NCCN Guideline | Rectal cancer.
19 Oct, 2022 | 14:25h | UTC
Consensus Recommendations | Radiation therapy in oligometastatic prostate cancer.
19 Oct, 2022 | 14:24h | UTCRelated: AUA/ASTRO Guideline: Clinically localized prostate cancer.
Cohort Study | 3-year outcomes of patients with spontaneous coronary artery dissection.
19 Oct, 2022 | 14:23h | UTCCanadian Spontaneous Coronary Artery Dissection Cohort Study: 3-Year Outcomes – Journal of the American College of Cardiology (link to abstract – $ for full-text)
Commentary: SCAD Heart Attacks: Outcomes Not as Bad as Previously Feared – Daytonews
M-A | Interventions associated with reduced loneliness and social isolation in older adults.
19 Oct, 2022 | 14:22h | UTCRelated:
Loneliness and health – Nature Reviews Disease Primers (if the link is paywalled, try this one)
The prevalence of loneliness across 113 countries: systematic review and meta-analysis – The BMJ
Social Isolation and Loneliness – World Health Organization
Psychological Distress and Loneliness Reported by US Adults in 2018 and April 2020 – JAMA
Review | Anesthetic considerations for endovascular treatment in stroke therapy.
19 Oct, 2022 | 14:20h | UTC